INTRODUCTION {#S6}
============

Serum testosterone concentrations have been reported to be depressed in men with chronic spinal cord injury (SCI) ([@R1]--[@R4]). Depressed levels of testosterone may be associated with infertility but also have a profound effect on body composition, musculoskeletal function, and mood ([@R5]--[@R8]). The potential reasons for low levels of testosterone in the SCI population may include chronic illness, stress, nutritional factors, and use of centrally-acting medications ([@R9]--[@R12]). Primary testicular failure, regardless of the etiology, may be responsible for low levels of circulating testosterone. Determination of whether an appropriate response to gonadal stimulation occurs will provide an answer as to whether the hypogonadism, frequently observed in men with SCI, is primary in origin, or a secondary to pituitary-hypothalamic dysfunction.

In men with SCI, gonadal stimulation to a conventional dose of human chorionic gonadotropin (hCG 4000 IU) has recently been reported to be associated with a normal gonadal response---that is, an appropriate rise in serum testosterone concentration to provocative stimulation, regardless of whether a subject was classified as being hypogonadal or eugonadal ([@R13]). Patron et al. reported that the magnitude of the testosterone response varies directly with the dose of hCG administered; circulating testosterone levels rise with a hCG dose of 375 IU and were maximally stimulated with a dose of 6,000 IU, the highest dose administered in this report ([@R14]). It is generally accepted that the dose of hCG to produce maximum testicular stimulation is between 6,000 and 10,000 IU ([@R14]--[@R16]). Of note, doses of hCG above approximately 2,000 IU are associated with pharmacological levels of plasma hCG and result in the Leydig cell being refractory to additional doses of hCG ([@R14], [@R17]). It may be speculated that the routine clinical test of Leydig cell function that serves to maximally stimulate the testes may not be sufficiently sensitive to identify more subtle forms of testicular dysfunction. In our previous report ([@R13]), the possibility was hypothesized that a lower dose of hCG would be able to differentiate between those who had lesser degrees of gonadal dysfunction from those who had responded adequately to a conventional dose of hCG. To address this possibility, stimulation of the testes was performed in a conventional manner, as well as with lower doses of hCG, in a cohort of men with chronic SCI.

MATERIALS AND METHODS {#S7}
=====================

Study cohort {#S8}
------------

Subjects were recruited from the James J. Peters VA Medical Center (JJP VAMC), Bronx, NY, and the Kessler Institute of Rehabilitation (KIR), West Orange, NJ. Otherwise healthy men, between the ages of 18 and 65 with chronic SCI (duration of injury \>1 year) or healthy men who were neurologically intact \[able-bodied (AB)\] were considered for screening for study eligibility. Because the group with SCI was recruited from a convenience sample, and approximately half of the SCI participants were found to have serum testosterone concentrations below the normal range without an apparent etiology for this condition, an effort was made to recruit a similar distribution in the AB group by randomly screening a convenience sample of individuals for serum testosterone concentration to permit identification of a sufficient number of subjects with low values for enrollment. Exclusion criteria consisted of the following conditions: acute illness; active thyroid disease; medications for depression, mood changes or any nervous system condition; centrally acting high blood pressure medications (i.e., guanethidine, reserpine, methyldopa, β-adrenergic blockers, clonidine, etc.); medications for gastrointestinal disorders; medication for heart disease; medications for seizures (i.e., dilantin or barbiturates); epilepsy; congestive heart failure; anti-cancer medications; antibiotics; pain medications; hormones (other than replacement doses); history of pituitary or testicular surgery; and/or less than 18 or older than 65 years of age. Abstinence from alcohol containing beverages was required for 48 hours prior to study procedures. The research study was approved by the Institutional Review Boards of the JJP VAMC and the KIR. Written informed consent was obtained from each subject prior to study participation.

Procedures {#S9}
----------

This was a prospective, open-label, parallel group investigation to differentiate between normal and abnormal testicular function in men with SCI. Baseline screening blood samples were taken from eligible participants to assist in differentiating and grouping those with normal serum testosterone concentrations (eugonadal: \>12.1 nmol/l) from those with low serum testosterone concentrations (hypogonadal: ≤12.1 nmol/l). To determine the differential secretion of testosterone to provocative stimulation, intramuscular hCG was administered at three dose concentrations (i.e., 400 IU, 2000 IU, and 4000 IU; Novarel, Ferring Pharmaceuticals, Parsippany, NJ, USA). Serial blood draws permitted a dose response curve to be obtained for each of the three stimulation tests. One of the three dose concentrations was administered each week, with each subject completing 3 consecutive days of testing for each of the hCG doses; hCG was administered intramuscularly on two consecutive days with blood collected for serum testosterone between 8 and 9 am prior to each of two injections, with subjects returning on day 3 for a final blood sample collection. The visits between the respective dose administrations were separated by a minimum of one week. On average, the participants completed the three-dose visits within 3-month period. A randomized order was used to administer the dose concentrations. Blood samples from the study visits were centrifuged and the serum was separated for the determination of testosterone using a commercial kit assay (ICN Biomedicals, Inc., Costa Mesa, CA). Serum samples were frozen at −70°C until batch processing at the completion of all testing. The serum testosterone concentration was determined in duplicate by radioimmunoassay, in accordance with the manufacturer's guidelines. The sensitivity for the testosterone assay was 3 nmol/l; the intra-assay CV were 9.6, 8.1, and 7.8% for testosterone concentrations of 3, 24, and 69 nmol/l, respectively; the inter-assay CV were 8.6, 9.1, and 8.4% for testosterone concentrations of 2, 21, and 56 nmol/l, respectively; the 2 standard deviation normal range for adult males is 9.7--30.5 nmol/l.

Statistical Analyses {#S10}
--------------------

Values are expressed as group mean ± SD. Chi-square tests were performed to determine group differences for categorical variables. AB and SCI participants were designated as being Eugonadal or Hypogonadal from the baseline serum testosterone concentration. To aid in statistical comparisons, the primary (AB or SCI) and gonadal status (Eugonadal or Hypogonadal) group designations were combined to produce a concatenated variable to form four groups: AB-Eugonadal, AB-Hypogonadal, SCI-Eugonadal, and SCI-Hypogonadal. Factorial analysis of variance (ANOVA) was performed to identify group differences for demographic \[age, height, weight, body mass index (BMI), duration of injury\] and baseline testosterone concentrations. To determine if group differences were present in the stimulated testosterone responses within (Day 1, 2 or 3) or between doses (hCG: 400 IU, 2000 IU and 4000 IU), a one-factor three level (dose) ANOVA with repeated measures on time (Day 1, 2 or 3) was performed. A separate repeated measures ANOVA was performed to determine if the serum testosterone concentrations were different at the respective Day 1 visits for each dose concentration. To further identify and describe significant main effects in the stimulated dose responses, Bonferoni post-hoc tests were applied to the respective time points and group comparisons. An *a priori* level of significance was set at p≤0.05. Statistical analyses were completed using IBM SPSS Statistics 21 (IBM, Armonk, NY, USA).

RESULTS {#S11}
=======

Demographic data for subjects in the AB-Eugonadal, AB-Hypogonadal, SCI-Eugonadal, and SCI-Hypogonadal groups are provided ([Table 1](#T1){ref-type="table"}). The groups were matched for demographic characteristics, but, by study design, differed for serum testosterone concentration with the SCI-Hypogonadal and AB-Hypogonadal groups having significantly reduced concentrations compared to their respective Eugonadal group ([Table 1](#T1){ref-type="table"}).

hCG Provocative Stimulation {#S12}
---------------------------

Provocative stimulation with hCG was performed at 3 doses; each dose of hCG was administered twice with blood collection over 3 consecutive days ([Figure 1](#F1){ref-type="fig"}). Day 1 serum testosterone concentrations---that is, prior to each of the three hCG doses--- were not significantly different within the eugonadal and hypogonadal groups. The serum testosterone concentration increased significantly for each group regardless of the dose of hCG (i.e., 400 IU, 2000 IU and 4000 IU). Within each group, the magnitude of the response of the serum testosterone concentration across the doses of hCG was similar. In all groups, the highest serum testosterone concentrations were observed by Day 3 of each hCG dose. Whereas the AB-Eugonadal and SCI-Eugonadal groups had statistically greater absolute serum testosterone responses than each of the Hypogonadal groups ([Figure 1](#F1){ref-type="fig"}), the average serum testosterone response above baseline for each of the three doses of hCG within and between the Eugonadal groups and the Hypogonadal groups was not significantly different. The mean serum testosterone concentration post-stimulation in both hypogonadal groups exceeded the lower limit of normal (e.g., \>12.1 nmol/l). Of note, not all subjects in the hypogonadal groups exceeded the lower limit of normal for the response of serum testosterone concentration at each one of the three doses of hCG: at the 400 IU dose, 3 of 14 SCI-Hypogonadal subjects had values less than the lower limit of normal for testosterone, as did 11 of 27 AB-Hypogonadal subjects; at the 2000 IU dose, 5 of 27 SCI-Hypogonadal subjects had values less than the lower limit of normal for testosterone, as did 5 of 27 AB-Hypogonadal subjects; at the 4000 IU dose, 3 of 14 SCI-Hypogonadal subjects had values less than the lower limit of normal for testosterone, as did 7 of 27 AB-Hypogonadal subjects. All subjects, in all groups responded with an adequate rise in serum testosterone concentration to one or more of the three doses of hCG. An exploratory post-hoc analysis failed to identify a demographic characteristic (i.e., age, weight, BMI, or in SCI, duration of injury) associated with subjects who failed to raise serum testosterone levels into the normal range after provocative stimulation.

DISCUSSION {#S13}
==========

Circulating testosterone concentrations have long been of interest to physicians caring for men with SCI because of well appreciated problems with fertility and impotence ([@R5], [@R18]--[@R25]), as well as the global effects on function and quality of life. Primary testicular and/or central dysfunction may lead to impaired spermatogenesis and infertility ([@R26]--[@R30]). In the general population, primary testicular failure is responsible for the majority of patients with male infertility; about half of these cases have no apparent etiology ([@R30]). Testosterone is also the major anabolic hormone in adult men. A deficiency of testosterone may be expected to have adverse effects on bone, soft tissue body composition, exercise tolerance, and psychological well-being ([@R6]--[@R8], [@R31]).

Serum testosterone concentrations have been reported to be depressed in persons with chronic SCI ([@R1]--[@R4]). Testicular failure of primary or secondary origin may be due to one or more etiologies (e.g., chronic illness, emotional stress, nutritional factors, medications, and local thermal gonadal conditions) ([@R9]--[@R11], [@R32]--[@R38]). In this study we hypothesized that by performing graded stimulation of the testes, a more subtle dysfunction of the Leydig cell, if present, may be revealed. Of note, the average response of SCI and AB participants, regardless of group affiliation by baseline testicular function (e.g., eugonadal or hypogonadal), was not significantly different. This finding supports and extends an earlier finding by our group that the testicular response to stimulation with a standard dose of hCG was generally appropriate. It should be mentioned that a minority of participants in each of the hypogonadal and eugonadal groups, regardless of whether SCI or AB, failed to raise serum testosterone concentrations into the normal range after administration of each of the three doses of hCG. As such, not all subjects with SCI can unequivocally be stated to have an absence of end organ dysfunction. The finding that hCG did not stimulate the testes to release testosterone into the normal range after each dose of hCG in those with SCI may merely represent chronic hypo-stimulation of the end organ by gonadotropins with the testes lacking the ability to respond adequately to a relatively short course of provocative stimulation. However, a mild primary end organ disorder may also be considered.

Gonadal release of testosterone by Leydig cells is under the regulation of the pituitary gland, and, more specifically, the episodic, pulsatile release of luteinizing hormone. In the classic feedback loop, if an individual has primary testicular failure, serum testosterone levels are depressed and plasma luteinizing hormone levels are elevated. Indeed, some investigators have reported elevated basal or stimulated levels of plasma luteinizing hormone when serum testosterone levels are low in cohorts of subjects with SCI ([@R39]--[@R41]). However, as in our report herein, other investigators have reported in persons with SCI that the basal levels of plasma luteinizing hormone were not elevated despite the presence of depressed serum testosterone concentrations ([@R12], [@R42], [@R43]). As previously discussed, a subset of our hypogonadal subjects with SCI did not have adequate responses to one or more doses of hCG. Indeed, individuals with such a hormonal picture (e.g., hypogonadal with normal basal plasma luteinizing hormone levels) may represent a heterogeneous group of individuals with a mixture of central and/or peripheral dysfunction, as determined by a variety of pituitary and gonadal stimulation tests in an AB population ([@R44]).

It is intriguing to consider the possibility that feedback from the testes could influence central gonadotropin function, and hence testicular function. Inhibin is a gonadal peptide that suppresses follicular stimulating hormone release and acts to regulate the function of the pituitary-gonadal axis ([@R45], [@R46]). Inhibin B is the predominant circulating and centrally active form that is also accepted as a marker of Sertoli cell function ([@R47]), and levels of inhibin have a diurnal variation in normal men, with a reduction of levels reported with advancing age ([@R48], [@R49]). With interruption of nervous innervation to the testes, it is likely that the normal diurnal patterns for both testosterone and inhibin are absent, with possible adverse central consequences on gonadotropin regulation. The hypothesized central dysregulation may result by interfering with the normal stimulatory effect of activins both on follicular stimulating hormone release, thus possibly decreasing hormone levels, and on gonadotropin releasing hormone receptor concentration in the basal and stimulated states ([@R50], [@R51]), decreasing receptor availability, and by doing so, modulating gonadotrope sensitivity to gonadotropin releasing hormone.

In an earlier article by our group, the pituitary-testicular axis was evaluated by the administration of conventional gonadotropin-releasing hormone stimulation test of the pituitary and hCG stimulation test of the gonads ([@R13]). An exaggerated gonadotropin response of the pituitary gland to provocative stimulation may suggest end organ dysfunction, however in the majority of subjects, the testes responded normally to stimulation, regardless of whether the participants were eugonadal or hypogonadal; as such, the possibility of diminished hypothalamic drive to the pituitary was raised as the most likely alternative explanation ([@R13]). The authors concluded that a disorder of the hypothalamic-pituitary axis was indeed present, but it was suggested that a graded provocative stimulation of the testes may be worthwhile to perform in an effort to unmask a more subtle deficit in end organ function. The work presented herein suggests that, even after provocative testing at two lower doses of hCG, testicular function was generally normal in a cohort of men with SCI, regardless of baseline gonadal status.

CONCLUSION {#S14}
==========

Stimulation of the testes with hCG in an incremental fashion in men with SCI demonstrated a normal response of testosterone, regardless of baseline gonadal status. This finding adds support to the prior work that suggested a secondary testicular failure, likely hypothalamic in origin, is present in a majority of those with depressed serum testosterone concentrations. However, because not all subjects responded appropriately to gonadal stimulation at each dose of hCG administered, the SCI population may also have a minority of individuals with impaired testicular function that may be partially responsible for depressed levels of serum testosterone.
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![Serum Testosterone Responses to Stimulation by hCG at 400 IU, 2000 IU and 4000 IU\
Data are presented as group mean with standard deviation bars redacted for enhanced visualization of group serum testosterone responses. Standard deviation is provided by dose (i.e., 400 IU, 2000 IU and 4000 IU) and Day (i.e., 1, 2, and 3) in each group for serum testosterone concentrations (400 IU- AB-Eugonadal: 9.0, 8.6, 6.7 nmol/l; AB- Hypogonadal: 3.3, 4.5, 6.5 nmol/l; SCI-Eugonadal: 6.2, 8.6, 9.5 nmol/l; SCI-Hypogonadal: 3.8, 6.8, 6.1 nmol/l); (2000 IU- AB-Eugonadal: 4.5, 5.2, 7.5 nmol/l; AB- Hypogonadal: 3.0, 4.5, 6.6 nmol/l; SCI-Eugonadal: 7.7, 8.2, 12.4 nmol/l; SCI-Hypogonadal: 5.2, 6.2, 10.4 nmol/l); and (4000 IU- AB-Eugonadal: 6.8, 8.6, 10.5 nmol/l; AB- Hypogonadal: 5.1, 8.6, 8.6 nmol/l; SCI-Eugonadal: 8.7, 7.2, 8.3 nmol/l; SCI-Hypogonadal: 5.2, 5.7, 7.7 nmol/l). The omnibus statistical models at each dose were statistically significant for group and time main effects, but no group by time interaction was observed. \*p\<0.01: SCI-Eugonadal vs. SCI-Hypogonadal; †p\<0.01: SCI-Eugonadal vs. AB-Hypogonadal; ‡p\<0.01: AB-Eugonadal vs. SCI-Hypogonadal; p\<0.01: AB-Eugonadal vs AB-Hypogonadal.](nihms841830f1){#F1}

###### 

Characteristics of the Study Groups

                                Spinal Cord Injury   Able-Bodied                                                                  p value                                                                                   
  ----------------------------- -------------------- ---------------------------------------------------------------------------- ------------- --------------------------------------------------------------------------- ----------
  n                             16                   14                                                                           11            27                                                                          \-
  Age (years)                   33 ± 7               41 ± 10                                                                      36 ± 7        36 ± 9                                                                      0.06
  Height (m)                    1.79 ± 0.08          1.78 ± 0.07                                                                  1.82 ± 0.10   1.76 ± 0.08                                                                 NS
  Weight (kg)                   88.1 ± 20.1          81.7 ± 15.2                                                                  87.6 ± 11.3   83.6 ± 14.0                                                                 NS
  BMI (kg/m^2^)                 27.3 ± 4.5           25.4 ± 4.0                                                                   26.4 ± 3.3    26.8 ± 3.8                                                                  NS
  DOI (years)                   11 ± 7               12 ± 10                                                                      \-            \-                                                                          NS
  Paraplegia/Tetraplegia (n)    11/5                 10/4                                                                         \-            \-                                                                          NS
  Total Testosterone (nmol/l)   17.4 ± 4.4           7.4 ± 3.8 [\*](#TFN3){ref-type="table-fn"},[†](#TFN4){ref-type="table-fn"}   16.7 ± 4.3    7.7 ± 2.3 [‡](#TFN5){ref-type="table-fn"},[¶](#TFN6){ref-type="table-fn"}   \<0.0001

Data are presented as group mean ± SD.

Abbreviations: BMI=body mass index; DOI= duration of injury; NS= not significant; SCI- spinal cord injury; AB= able-bodied.

p\<0.0001: SCI-Eugonadal vs. SCI-Hypogonadal;

p\<0.0001: AB-Eugonadal vs. SCI-Hypogonadal;

p\<0.0001: AB-Eugonadal vs. SCI-Hypogonadal;

p\<0.0001: AB-Eugonadal vs AB-Hypogonadal.
